Description     Claims     Drawing  

WO2014096551A   [0005]  [0099] 
US5635483A   [0042]  [0181] 
US134826   [0042]  [0181] 
US20060074008A   [0042]  [0181] 
US2006022925A   [0042]  [0181] 
WO2014177771A   [0099]  [0248]  [0297]  [0558]  [0567]  [0570]  [0571]  [0572]  [0572]  [0573]  [0576]  [0576] 
WO9734632A   [0248]  [0248] 
WO9515769A   [0248] 
US20090274713A   [0285] 
US7091186B   [0294] 
US7553816B   [0294] 
US6214345B   [0294] 
US7090843B   [0294] 
US7223837B   [0294] 
US20040018194A   [0294] 
US20040121940A   [0294] 
US20060116422A   [0294] 
US20070258987A   [0294] 
US20080213289A   [0294] 
US20080241128A   [0294] 
US20080311136A   [0294] 
US20080317747A   [0294] 
US20090010945A   [0294] 
WO2011051484A   [0295] 
WO2011054837A   [0295] 
WO2001083448A   [0295] 
WO2007011968A   [0295] 
WO2008083312A   [0295] 
WO2008074004A   [0295] 
WO2007089149A   [0295] 
DE4415463   [0295] 
US7811572B   [0296] 
US6411163B   [0296] 
US7368565B   [0296] 
US8163888B   [0296] 
US20110003969   [0296] 
US20110166319A   [0296] 
US20120253021A   [0296] 
US20120259100A   [0296] 
US20140288280A   [0296] 
US7837980B   [0296] 
US20040157782A   [0296] 
US20050238649A   [0296] 
US04038392W   [0296] 
WO201417771A   [0595] 
EP19790300469A   [0652] 
US5208020A   [0652] 
US6441163B   [0652] 

Bioconjug. Chem.   [0004] 
Int. J. Oncol.   [0042]  [0181] 
Mol. Cancer Ther.   [0042]  [0181] 
J. Nat. Prod.   [0042]  [0181] 
Bioconj. Chem.   [0042]  [0181] 
Toxins   [0060] 
Pharm. Pat. Analyst   [0060] 
Bioconj. Chem.   [0065]  [0197] 
Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates   [0277]  [0521] 
Proc. Natl. Acad. Sci. USA   [0283] 
Int. J. Cancer   [0283] 
Adv. Drug Deliv. Rev.   [0295] 
Cancer Immunol. Immunother.   [0295] 
Cancer Cell   [0295] 
Nat. Rev. Cancer   [0295] 
Cuff. Opin. Investig. Drugs   [0295] 
Adv. Drug Deliv. Rev.   [0295] 
β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update   [0295] 
Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates   [0295] 
Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue   [0295] 
Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy   [0295] 
Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT   [0295] 
Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT   [0295] 
Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA   [0295] 
Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer   [0295] 
Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity   [0295] 
Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065   [0295] 
Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies   [0295] 
Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug monotherapy of cancer   [0295] 
Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies   [0295] 
Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy   [0295] 
Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy   [0295] 
Duocarmycin-based prodrugs for cancer prodrug monotherapy   [0295] 
Enantio- and diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of cancer by epoxide opening   [0295] 
Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins   [0295] 
Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy   [0295] 
Investigation of reactivity and selectivity of DNA-alkylating duocarmycin analogues by high-resolution mass spectrometry   [0295] 
Enzyme and proton-activated prodrugs for a selective cancer therapy   [0295] 
Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug   [0295] 
Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy   [0295] 
A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs   [0295] 
Stereoselective synthesis of (1-alkoxyalkyl) alpha- and beta-D-glucopyranosiduronates (acetal-glucopyranosiduronates): a new approach to specific cytostatics for the treatment of cancer   [0295] 
Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs   [0295] 
Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs   [0295] 
Synthesis of Fluorescence-Labelled Glycosidic Prodrugs Based on the Cytotoxic Antibiotic Duocarmycin   [0295] 
The Two Faces of Potent Antitumor Duocarmycin-Based Drugs: A Structural Dissection Reveals Disparate Motifs for DNA versus Aldehyde Dehydrogenase 1   [0295] 
Synthesis and Biological Evaluation of Novel Analogues and Prodrugs of the Cytotoxic Antibiotic CC-1065 for Selective Cancer Therapy   [0295] 
Prodrugs of the Cytostatic CC-1065 That Can Be Activated in a Tumor-Selective Manner   [0295] 
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins   [0295] 
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum   [0295] 
Cancer J   [0296] 
Cancer Res.   [0379] 
Synthesis   [0541] 
J. Org. Chem.   [0541] 
Angew. Chem. Int. Ed.   [0579]  [0580] 
Org. Lett.   [0582] 
Org. Biomol. Chem.   [0582] 
Chemistry & Biology   [0653] 
Cancer Res   [0654] 
Mol. Cancer Ther.   [0655] 
J. Natl. Cancer Inst.   [0656] 
Chem. Eur. J.   [0657]